ArrowMark Colorado Holdings’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

ArrowMark Colorado Holdings’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-2,684	Closed	-$45K	–	349
2019 Q2	$45K	Hold	2,684	–	–	﹤0.01%	310
2019 Q1	$45K	Hold	2,684	–	–	﹤0.01%	313
2018 Q4	$31K	Hold	2,684	–	–	﹤0.01%	335
2018 Q3	$107K	Hold	2,684	–	–	﹤0.01%	340
2018 Q2	$76K	Hold	2,684	–	–	﹤0.01%	339
2018 Q1	$41K	Hold	2,684	–	–	﹤0.01%	324
2017 Q4	$88K	Sell	2,684 -318	-11%	-$8.57K	﹤0.01%	330
2017 Q3	$70K	Buy	+3,002	New	+$33.7K	﹤0.01%	329
2016 Q4	–	Sell	-235,515	Closed	-$1.72M	–	464
2016 Q3	$1.72M	Buy	235,515 +88,820	+61%	+$600K	0.03%	219
2016 Q2	$745K	Sell	146,695 -68,045	-32%	-$1.25M	0.02%	233
2016 Q1	$4.62M	Buy	214,740 +2,681	+1%	+$56.8K	0.1%	145
2015 Q4	$6.48M	Buy	212,059 +143,884	+211%	+$4.22M	0.18%	127
2015 Q3	$2.27M	Buy	68,175 +15,014	+28%	+$847K	0.06%	191
2015 Q2	$2.47M	Buy	+53,161	New	+$1.99M	0.06%	200

Other funds holding MRNS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

ArrowMark Colorado Holdings's MRNS Position: Q3 2019 in Review

ArrowMark Colorado Holdings sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2019, closing a stake of 2,684 shares — an estimated $45K sold.

ArrowMark Colorado Holdings first reported a position in MRNS in Q2 2015 and held it in 14 quarters. The position peaked at $6.48M in Q4 2015. 64 funds tracked by Wall St. Rank hold MRNS as of Q3 2019.

ArrowMark Colorado Holdings reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2019 after selling out during the quarter.
ArrowMark Colorado Holdings sold 2,684 Marinus Pharmaceuticals, Inc shares in Q3 2019, an estimated $45K.
ArrowMark Colorado Holdings first reported a position in Marinus Pharmaceuticals, Inc in Q2 2015 and held it in 14 quarters.
ArrowMark Colorado Holdings's Marinus Pharmaceuticals, Inc position peaked at $6.48M in Q4 2015.
64 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2019.

Based on ArrowMark Colorado Holdings's 13F filing for Q3 2019, filed 14 Nov 2019.